Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

NeoGenomics, Inc. - Common Stock (NQ:NEO)

6.310 +0.070 (+1.12%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about NeoGenomics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
Why NeoGenomics (NEO) Shares Are Trading Lower Today
Shares of oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) fell 21.5% in the afternoon session after the company reported weak fourth-quarter results, with revenue falling below Wall... 
Via StockStory
NeoGenomics (NASDAQ:NEO) Misses Q4 Sales Targets
Oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) missed Wall Street’s revenue expectations in Q4 CY2024, but sales rose 10.6% year on year to $172 million. On the other hand, the... 
Via StockStory
NeoGenomics Reports Fourth Quarter and Full Year 2024 Results
From NeoGenomics, Inc.
Via Business Wire
NeoGenomics (NEO) To Report Earnings Tomorrow: Here Is What To Expect
Oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) will be reporting results tomorrow morning. Here’s what to look for. 
Via StockStory
5 Analysts Assess NeoGenomics: What You Need To Know
 
Via Benzinga
Evaluating NeoGenomics: Insights From 4 Financial Analysts
 
Via Benzinga
Earnings Scheduled For February 18, 2025
 
Via Benzinga
Expert Ratings For NeoGenomics
 
Via Benzinga
NeoGenomics to Report Fourth Quarter and Full Year 2024 Financial Results on February 18, 2025
From NeoGenomics, Inc.
Via Business Wire
Stock Market Rises On Tame Inflation, Bank Earnings: Weekly Review
Many stocks flashed buy signals as the major indexes rose to or above key levels. 
Via Investor's Business Daily
Topics Economy
NeoGenomics Is On The Upswing, Reversing A CEO-Tied Sell-Off, On Bullish Long-Term Guidance
The company expects sales to grow 12% to 13% annually in the long term. 
Via Investor's Business Daily
NeoGenomics Provides 2025 Financial Guidance and Updates Long-Range Financial Plan
From NeoGenomics, Inc.
Via Business Wire
Adaptive Biotechnologies and NeoGenomics Partner to Expand Access to Personalized Disease Monitoring for Blood Cancer Patients
Pairing Adaptive Biotechnologies’ clonoSEQ MRD results with NeoGenomics’ COMPASS and CHART assessment services empowers clinicians and patients with meaningful insights across the treatment continuum 
From Adaptive Biotechnologies
Via GlobeNewswire
NeoGenomics Shares Are Falling Today: What's Going On?
Shares of NeoGenomics, Inc. (NASDAQ: NEO) are, after the company announced that CEO Chris Smith will retire effective April 1 2025. 
Via Benzinga
NeoGenomics Announces Chief Executive Officer Succession
From NeoGenomics, Inc.
Via Business Wire
NeoGenomics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
From NeoGenomics, Inc.
Via Business Wire
NeoGenomics’ Newly Published Study Underscores Potential of ctDNA as a Predictive Tool for Monitoring Patients with High-Risk Melanoma
From NeoGenomics, Inc.
Via Business Wire
NeoGenomics to Present Key Research on Hematologic Malignancies at the 2024 American Society of Hematology Annual Meeting
From NeoGenomics, Inc.
Via Business Wire
NeoGenomics to Present New Data at AMP 2024, Highlighting the Impact of ctDNA and NGS for Advancing Cancer Diagnostics and Personalized Treatment
From NeoGenomics, Inc.
Via Business Wire
Felicia Williams Joins NeoGenomics Board of Directors
From NeoGenomics, Inc.
Via Business Wire
NeoGenomics to Participate in the Piper Sandler 36th Annual Healthcare Conference
From NeoGenomics, Inc.
Via Business Wire
NeoGenomics Reports Third Quarter 2024 Results
From NeoGenomics, Inc.
Via Business Wire
Earnings Scheduled For November 14, 2024
 
Via Benzinga
NeoGenomics Receives New York State Approval for Neo Comprehensive™ Solid Tumor Test
From NeoGenomics, Inc.
Via Business Wire
NeoGenomics to Report Third Quarter 2024 Financial Results on Nov. 5, 2024
From NeoGenomics, Inc.
Via Business Wire
NeoGenomics Launches AML Express for Rapid Genetic Profiling of Acute Myeloid Leukemia
From NeoGenomics, Inc.
Via Business Wire
NeoGenomics Announces New RaDaR Technology and Resolution of RaDaR 1.0 Litigation
From NeoGenomics, Inc.
Via Business Wire
NeoGenomics to Present New Data at ESMO 2024, Highlighting the Value of ctDNA and NGS for Advancing Cancer Diagnostics and Personalized Treatment
From NeoGenomics, Inc.
Via Business Wire
NeoGenomics to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
From NeoGenomics, Inc.
Via Business Wire
Shake Shack And Lumen Tech Are Among Top 7 Mid Cap Stocks With Max Gains Last Week (July 28-August 3): Are The Others In Your Portfolio?
Seven mid-cap stocks that performed well last week: LUMN, SHAK, PSN, CWAN, RGEN, FTDR, and NEO. Check if they're in your portfolio! 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS